The Impact of Anaemia on Outcomes, Admissions, and Costs in Patients with Chronic Kidney Disease in Two Public Nephrology Practices in Queensland: A CKD.QLD Registry Study
Table 1
Baseline characteristics of the two cohorts.
Total participants
Site A
Site B
Overall
N (%)
N (%)
N (%)
1,305 (56.7%)
998 (43.3%)
2,303 (100%)
Follow-up (years)
Mean (SD)
4.2 (2.2)
3.4 (1.8)
3.9 (2.1)
Range
0–7.12
0.01–7.02
0–7.1
Gender
Male
679 (52.0)
555 (55.6)
1234 (53.6)
Female
626 (47.9)
443 (44.4)
1069 (46.4)
Age (years)
Mean (SD)
65.8 (16.6)
64.2 (15.2)
65.1 (16.0)
Range
17.7–98.6
18.1–96.3
17.7–98.6
Age categories
<55
308 (23.6)
238 (23.8)
546 (23.7)
55–<65
183 (14.0)
211 (21.1)
394 (17.1)
65–<75
370 (28.3)
270 (27.1)
640 (27.8)
≥75
444 (34.0)
279 (27.9)
723 (31.4)
BMI (kg/m2)
Mean (SD)
30.5 (7.9)
31.8 (0.25)
31.1 (8.0)
BMI category
Underweight
15 (1.4)
11 (1.1)
26 (1.3)
Normal
241 (22.5)
171 (17.1)
412 (19.9)
Overweight
340 (31.7)
288 (28.9)
628 (30.3)
Obese
363 (33.9)
398 (39.9)
761 (36.8)
Morbidly obese
112 (10.4)
130 (13.0)
242 (11.7)
Comorbidities
Diabetes
556 (42.6)
444 (44.5)
1000 (43.4)
Neoplasms
327 (25.1)
240 (24.0)
567 (24.6)
CKD stage
1
95 (7.3)
68 (6.8)
163 (7.1)
2
142 (10.9)
126 (12.6)
268 (11.6)
3a
216 (16.5)
142 (14.2)
358 (15.5)
3b
417 (31.9)
293 (29.4)
710 (30.8)
4
361 (27.7)
275 (27.6)
636 (27.6)
5
74 (5.7)
94 (9.4)
168 (7.3)
Proteinuria/albuminuria category
Normal
370 (29.3)
213 (21.6)
583 (25.9)
Mild proteinuria
405 (32.1)
268 (27.2)
673 (29.9)
Macroproteinuria
486 (38.5)
505 (51.2)
991 (44.1)
Haemoglobin (g/L)
Mean (SD)
125.3 (19.7)
127.7(19.7)
126.3 (19.7)
Anaemia category
No anaemia
687 (52.6)
567 (56.8)
1254 (54.4)
Mild
347 (26.6)
269 (26.9)
616 (26.7)
Moderate
258 (19.8)
152 (15.2)
410 (17.8)
Severe
13 (1)
10 (1)
23 (1)
Primary renal diagnosis (PRD)
RVD†
465 (35.6)
174 (17.4)
639 (27.7)
DN‡
232 (17.8)
269 (26.9)
501 (21.7)
GN§
151 (11.6)
154 (15.4)
305 (13.2)
GRD¶
87 (6.7)
39 (3.9)
126 (5.5)
Other
199 (15.3)
241 (24.1)
440 (19.1)
Uncertain
171 (13.1)
121 (12.1)
292 (12.7)
Index of Relative Socioeconomic Disadvantage (IRSD)
